Despite decades of progress in medical innovation and healthcare delivery, coronary artery disease (CAD) remains the number one cause of death among Americans. Rapid, safe and effective removal of blood clots, or thrombus, is the key to allowing definitive treatment of heart attack victims, saving their lives or improving their quality of life. With its pioneering AngioJet® Rheolytic™ Thrombectomy System, Possis Medical is the leader in coronary thrombectomy, or removal of blood clots from coronary arteries and saphenous vein bypass grafts. The coronary market in the U.S. is the largest segment of Possis Medical’s business and we are investing significant resources to grow this business in the future. However, peripheral vascular disease (PVD) is strongly associated with coronary artery disease and a major predictor of death from CAD. The AngioJet System alone, and in conjunction with appropriate drug regimens, is a powerful tool in removing blood clots from the legs, often preserving the limb and allowing patients to maintain mobility and an active lifestyle. Blood clots in the legs can occur in the arteries and in the veins, vascular territories with their own distinct treatment challenges for physicians. PVD does not yet have the visibility of coronary artery disease, and some conditions, like deep vein thrombosis (DVT), are vastly undertreated. As Possis helps its physician-customers pioneer this growing therapeutic area, we thought we would tell you the other hald of the story.